Allegro Ophthalmics Announces Last Patient Enrolled in DEL MAR Phase 2b Clinical Trial of Luminate® for the Treatment of Diabetic Macular Edema

by Business Wire • 2016/01/05 • 0 Comments

SAN JUAN CAPISTRANO, Calif.--(BUSINESS WIRE)--Allegro Ophthalmics, LLC today announced completion of enrollment in its Phase 2b trial that is evaluating the safety and efficacy of Luminate® (ALG-1001) in patients with diabetic macular edema.

← Clearside Biomedical, Inc. Announces Positive Topline Data from Phase 2 Clinical Trial for the Treatment of Macular Edema Associated with Non-Infectious Uveitis

VIDEO: Surgeon highlights topics presented at CEDARS/ASPENS meeting →

Post navigation